pds0101
Generic: Versamune® HPV·Code: PDS0101
pds0101: sourced relationships with 1 company · 1 clinical trial tracked.
pds0101 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect pds0101 to PDSB; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could pds0101 → PDSB affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
HPV16-positive first-line treatment of recurrent/metastatic head and neck squamous cell carcinomaAnal CancerCervical CancerHIV (Human Immunodeficiency Virus)
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| PDS Biotechnology Corp (PDSB) HPV16-positive first-line treatment of recurrent/metastatic … | Phase 3 |
Clinical Trial Registry Records (1)
CASCADE: A Single-Arm, Open-Label Clinical Phase II Trial of the Safety and Immunogenicity of PDS0101 in People Living With HIV
Primary endpoint: Safety: Number of Grade 3 or greater adverse events (AE) at least possibly related to PDS0101.
Interventionalopen0 enrolledStarted 2026-04Completion 2026-123 sites · Puerto Rico, United StatesUniversity of California, San Diego
Frequently asked questions
Which companies have sourced relationships with pds0101?
pds0101 has dated SEC/FDA relationship records for PDS Biotechnology Corp.
How many clinical trials involve pds0101?
BioSniper tracks 1 clinical trial involving pds0101.